Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.
about
Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo ExposuresImpact of prior healthcare-associated exposure on clinical and molecular characterization of methicillin-susceptible Staphylococcus aureus bacteremia: results from a retrospective cohort studyDoes Preoperative Antimicrobial Prophylaxis Influence the Diagnostic Potential of Periprosthetic Tissues in Hip or Knee Infections?β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.Prevalence of Staphylococcus aureus Nasal Carriage in Human Immunodeficiency Virus-Infected and Uninfected Children in Botswana: Prevalence and Risk Factors.Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision.Associations between resistance phenotype and gene expression in response to serial exposure to oxacillin and ciprofloxacin in Staphylococcus aureus.Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus.
P2860
Q36096382-FDD5D9A4-02C5-4CBB-8AC0-28DADF842BCEQ36152264-165CEB46-49ED-43B9-B56C-F5DBC037A0F7Q36391716-FD94AE8E-8AB8-4E55-B5ED-E3ED7DC19165Q39051288-D3F5166A-B179-4768-9C37-9931CD9458BFQ39390846-6DE38AA2-CCD9-49DF-AD9B-6F7947028A6AQ44877139-7883A395-3562-4602-AA38-899F1D8C940FQ47601682-3F1C5F7A-6E1A-4AEC-9B37-221E6B7E4EE8Q49796007-AE40AA24-53A4-4980-BD5D-2C8A8D8D2401
P2860
Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@en
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@nl
type
label
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@en
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@nl
prefLabel
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@en
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@nl
P2093
P2860
P356
P1476
Rationale for eliminating Stap ...... or cefoxitin, and ceftaroline.
@en
P2093
Howard S Gold
Janet A Hindler
Jennifer Dien Bard
P2860
P304
P356
10.1093/CID/CIU043
P407
P577
2014-01-22T00:00:00Z